Table 4.
The FQPA factor determinations for non-dietary exposures
| FQPA factor for incidental oral exposure | FQPA factor for dermal exposure | FQPA factor for inhalation exposure | |
|---|---|---|---|
| Number of pesticides for which an FQPA factor was assigned for this exposure scenario | 27 | 16 | 27 |
| Number of pesticides for which this exposure scenario has an FQPA factor greater than 1X | 4 | 5 | 11 |
| Percentage of pesticides for which this exposure scenario has an FQPA factor greater than 1X | 15% | 31% | 41% |
| Which pesticides have an FQPA factor greater than 1X for this scenario | Chlorpropham, glufosinate, tebuconazole, thiophanate-methyl | Chlorpropham, glufosinate, iprodione, tebuconazole, thiophanate-methyl | 2,4-D, chlorothalonil, chlorpropham, cyprodinil, dicamba BAPMA salt, glufosinate, iprodione, tebuconazole, thiabendazole, thiophanate-methyl, trifloxystrobin |
| 1,3-Dichloropropene | N/A | N/A | 1X (4 scenarios for different exposure durations: acute, short-term; intermediate-term; and long-term) |
| 2,4-D | 1X (1 scenario for short- and intermediate-term) | N/A | 10X (1 scenario for all exposure durations) |
| Acetamiprid | 1X (2 scenarios for different exposure durations: short- and intermediate-term; and long-term) | 1X (2 scenarios for different exposure durations: short- and intermediate-term; and long-term) | 1X (1 scenario for short- and intermediate-term) |
| Azoxystrobin | 1X (1 scenario for short- and intermediate-term) | N/A | N/A |
| Boscalid | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
| Captan | 1X (1 scenario for short-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
| Chlorothalonil | 1X (2 scenarios for different exposure durations: short-term; and intermediate-term) | N/A | 3X and 30X (2 scenarios for different exposure durations: acute inhalation with 3X FQPA factor; and short- and intermediate-term inhalation with 30X FQPA factor) |
| Chlorpropham | 10X (1 scenario for short- and intermediate-term) | 10X (1 scenario for short- and intermediate-term) | 10X (1 scenario for short- and intermediate-term) |
| Clothianidin | 1X (1 scenario for short-term) | 1X (1 scenario for all durations) | 1X (1 scenario for all durations) |
| Cyprodinil | 1X (1 scenario for short-term) | N/A | 10X (1 scenario for short- and intermediate-term) |
| Dicamba | 1X (1 scenario for short- and intermediate-term) | N/A | 2 scenarios: 1X for short-, intermediate- and long-term inhalation scenario for dicamba acid; 10X for short-, intermediate- and long-term inhalation scenario for dicamba BAPMA salt |
| Dimethomorph | 1X (1 scenario for short-term) | N/A | N/A |
| Fenhexamid | 1X (1 scenario for short- and intermediate-term) | N/A | 1X (1 scenario for short- and intermediate-term) |
| Fludioxonil | 1X (1 scenario for short- and intermediate-term) | N/A | 1X (1 scenario for short- and intermediate-term) |
| Fluopicolide | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
| Glufosinate | 10X (1 scenario for short- and intermediate-term) | 10X (1 scenario for short- and intermediate-term) | 10X (1 scenario for acute, short- and intermediate-term) |
| Glyphosate | 1X (1 scenario for short- and intermediate-term) | N/A | N/A |
| Imidacloprid | 1X (1 scenario for all durations) | 1X (1 scenario for all durations) | 1X (1 scenario for all durations) |
| Iprodione | N/A | 10X (1 scenario for dermal and inhalation, short- and intermediate-term) | |
| Metalaxyl/Mefenoxam | 1X (1 scenario for short- and intermediate-term) | N/A | 1X (1 scenario for short- and intermediate-term) |
| Metolachlor | 1X (1 scenario for short-term) | 1X (1 scenario for short- and intermediate-term exposure for children) | 1X (1 scenario for short- and intermediate-term) |
| Paraquat | 1X (1 scenario for short-term) | 1X (1 scenario for short-term) | 1X (1 scenario for short-term) |
| Pendimethalin | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
| Pyraclostrobin | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
| Pyrimethanil | N/A | 1X (1 scenario for short- and intermediate-term) | 1X (1 scenario for short- and intermediate-term) |
| Spinetoram | 1X (1 scenario for short- and intermediate-term) | N/A | 1X (1 scenario for short- and intermediate-term) |
| Tebuconazole | 3X (1 scenario for short-term) | 3X (1 scenario for short-term) | 3X (1 scenario for short-term) |
| Thiabendazole | 1X (2 scenarios, for short- and intermediate-term exposure for children and for short- and intermediate-term exposure for adults) | N/A | 10X (1 scenario for short- and intermediate-term) |
| Thiophanate-methyl | 3X (1 scenario for short- and intermediate-term) | 3X (2 scenarios for short- and intermediate-term, and for long-term exposures) | 3X (2 scenarios for short- and intermediate-term, and for long-term exposures) |
| Trifloxystrobin | 1X (1 scenario for short-term) | N/A | 10X (1 scenario for all durations) |
N/A not available, indicating that an FQPA factor was not assigned for this exposure scenario